{"id":"W4380085040","doi":"10.1002/hon.3163_91","title":"COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Tolerability; Lymphoma; Follicular lymphoma; Gastroenterology; Dosing; Oncology; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002516595,0.0003196513,0.0006204767,0.0001493494,0.0001277761,0.0002990179,0.0002125489,0.0002541062,0.001818766],"category_scores_gemma":[0.0001730994,0.0001432261,0.0002523597,0.0001614873,0.0001970762,0.0001876551,0.0001894036,0.0006406014,0.00045549],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002977247,"about_ca_system_score_gemma":0.0003021974,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003515862,"about_ca_topic_score_gemma":0.0007216934,"domain_scores_codex":[0.9999096,0.00002775123,0.000005885184,0.00001489133,0.00001394181,0.00002795667],"domain_scores_gemma":[0.9998994,0.00001630686,0.00002409456,0.000009487058,0.000004422474,0.00004629313],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1893418,0.02454554,0.01973813,0.0008414675,0.0007277751,0.0007620071,0.0003384394,0.002678824,0.3144186,0.0002049081,0.003306898,0.4430956],"study_design_scores_gemma":[0.07878833,0.6897941,0.09145544,0.00006914029,0.0006226684,0.003404761,0.0001200529,0.002411393,0.1193746,0.0001626674,0.01375624,0.00004073559],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980024,0.000914879,0.0001986307,0.00004730676,0.000007588314,0.0001042602,0.0001229052,0.00004562873,0.0005564756],"genre_scores_gemma":[0.9980021,0.0005549086,0.0002232977,0.00005001876,0.00002163206,0.00006472469,0.0003628921,0.000007656497,0.0007127465],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001818766,"threshold_uncertainty_score":0.006084383,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03924295893968783,"score_gpt":0.3232265847332438,"score_spread":0.283983625793556,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}